FDA gave olomorasib breakthrough therapy status for KRAS G12C pancreatic cancer. What the designation means, who it applies to, and what it does not prove.
FDA Grants Breakthrough Therapy Status to a Pancreatic Cancer Drug for a Mutation Found in Roughly 1 in 50 Patients
by | Aug 6, 2026 | Uncategorized | 0 comments
Recent Comments